
Swiss-founded data-driven medicine software company Sophia Genetics (Nasdaq: SOPH) has announced two collaborations to connect its AI-powered analytics DDM platform with sequencers developed by Element Biosciences and Complete Genomics.
In their deal, Complete Genomics and Sophia Genetics will unite to provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze